Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, host Sarah Hughan tells all on AdAlta (ASX:1AD) recruiting a team of world leaders in idiopathic pulmonary fibrosis to form a company clinical advisory board.

Therapeutic options for the debilitating inflammatory lung disease are limited and there’s currently no cure.

Tune in to get the latest.

 

While AdAlta is a Stockhead advertiser, it did not sponsor this content.

Read MoreHealthMedtech

You might be interested in